ReviewCPT: pharmacometrics & systems pharmacology2026
Integration of Machine Learning With PBPK and QSAR Modeling Approaches to Facilitate Drug Discovery and Development.
Review in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial Intelligence in the Design and Development of Nanoparticle Drug Delivery Systems: A Systematic Review.Advances in pharmacological and pharmaceutical sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
This review examines the application of machine learning (ML) in physiologically based pharmacokinetic (PBPK) modeling through improved prediction of input parameters, particularly via quantitative structure-activity relationship (QSAR) models, for absorption, distribution, metabolism, and excretion (ADME) properties across drug development phases. Traditional PBPK models, while mechanistically sound, face limitations in applicability domain when compound-specific physicochemical and biochemical parameters (e.g., partition coefficients, metabolic clearance rates, plasma protein binding) cannot be reliably determined or estimated for novel chemicals. ML-enhanced QSAR models address these input parameter limitations by predicting required parameters directly from chemical structure, thereby extending PBPK applicability to diverse chemical space without altering the mechanistic model framework itself. Recent advances in ML-powered QSAR methodology generate higher-quality predictions of partition coefficients, clearance rates, and binding parameters. When these ML-predicted parameters are integrated as inputs into conventional PBPK frameworks, the resulting simulations often demonstrate significantly improved predictive accuracy compared to PBPK models using conventional regression-based QSAR inputs. This workflow-wherein ML enhances QSAR prediction quality, which subsequently improves PBPK simulation reliability through better input parameters-facilitates critical drug discovery and development decisions, from early candidate selection to clinical translation and safety assessment, potentially reducing pharmacokinetic-related drug candidate failures. However, challenges remain, including limited chemical diversity in QSAR training data sets, model interpretability concerns, and evolving regulatory considerations for ML-derived parameters in PBPK submissions. Future developments point toward seamless integration of ML-enhanced QSAR predictions as validated inputs for mechanistic PBPK models through standardized validation approaches and collaboration among academia, industry, and regulatory bodies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.